Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 10Q

I can't beleive that the BK judge can't see that DL (on purpose) is dragging us down with him...making no real effots to sell license agreements (who remains at TPL anyway to conduct such efforts?) and dragging his feet on splitting up the pool with the new licensing agent...

I am glad that a shareholder (or other party) filed our letter (stand alone and not burried as an exhibit to a filing). All of this crap needs to be brought into the light.

_______________________________________________________

We Have Reported Licensing Income In Prior Fiscal Years Which May Not Be Indicative Of Our Future Income.

We have entered into license agreements through our joint venture with TPL and have reported income from the joint venture for the fiscal years 2006 to 2011 and 2013 to 2014. The joint venture has recorded a loss for the six months ended November 30, 2014. Because of the uncertain nature of the negotiations that lead to license revenues, pending litigation with companies which we allege have infringed on our patent portfolio, the possibility of legislative action regarding patent rights, and the possible effect of new judicial interpretations of patent laws, we may not receive revenues from such agreements in the future consistent with amounts received in the past, and we may not receive future revenues from license agreements at all.

Share
New Message
Please login to post a reply